Abstract:Alzheimer's disease (AD) is a progressive age‐related neurodegenerative brain disorder that destroys memory and other important mental functions. This review article comprehensively summarized the recent advancements in galantamine and its hybrid analogs as potential therapeutic agents for the management of AD. Furthermore, we also provided the design, synthesis, and SAR analysis of the galantamine‐based compounds used in the last decades for the management of AD. Alzheimer's disease (AD) is a progressive chronic age‐related neurodegenerative brain disorder characterized by the loss of memory and other cognitive functions. The exact etiology of AD is still under investigation, however several factors such as low level of neurotransmitter acetylcholine (ACh), aggregation of amyloid beta (Aβ) in the form of Aβ plaques, hyperphosphorylation of tau protein into neurofibrillary tangles (NFTs), oxidative stress, and metal ion imbalance are the major hallmarks of this disease. Of the multiple hypotheses for AD, the amyloid‐β (Aβ) and cholinergic hypothesis are the main targeting hypotheses for AD. Some researchers hypothesized that the primary event associated with the cholinergic neurotransmitter (acetylcholine) is memory loss and cognitive impairment. Due to the disease's complicated pathogenesis, long‐term therapy with a single target candidate is futile. As a result, multitargeted and multifunctional therapies have emerged. Various research teams are concentrating on addressing multiple disease factors through hybridization techniques. Consequently, this hybridization approach has been applied to all core scaffolds, including galantamine. In this article, we tried to provide a thorough overview of the most recent developments on galantamine, a prospective AChE inhibitor, and its hybrid analogs as possible therapeutic agents for treating AD. Furthermore, we also provided the design, synthesis, and SAR analysis of the galantamine‐based compounds used in the last decades for the management of AD.

3D-QSAR Studies of Galanthamine and Analogs

Design, Synthesis and Biological Evaluation of 2-Styryl-5-hydroxy-4-pyrone Derivatives and Analogues As Multiple Functional Agents with the Potential for the Treatment of Alzheimer's Disease.

Palladium-Catalyzed Synthesis, Acetylcholinesterase Inhibition, and Neuroprotective Activities of N -Aryl Galantamine Analogues

Static Binding and Dynamic Transporting-Based Design of Specific Ring-Chain-Ring Acetylcholinesterase Inhibitor: From Galantamine to Natural Product

AChE inhibitory activity of N-substituted natural galanthamine derivatives

2D-SAR and 3D-QSAR analyses for acetylcholinesterase inhibitors

Design, Synthesis and Evaluation of Galanthamine Derivatives As Acetylcholinesterase Inhibitors

Searching for the Multi-Target-Directed Ligands Against Alzheimer'S Disease: Discovery of Quinoxaline-Based Hybrid Compounds with Ache, H3r and Bace 1 Inhibitory Activities

Recent advances in the total synthesis of galantamine, a natural medicine for Alzheimer's disease

Discovery of Novel Acetylcholinesterase Inhibitors as Potential Candidates for the Treatment of Alzheimer's Disease

Identification of N-phenyl-3-methoxy-4-pyridinones As Orally Bioavailable H3 Receptor Antagonists and Β-Amyloid Aggregation Inhibitors for the Treatment of Alzheimer's Disease.

Systems pharmacology-based drug discovery from Amaryllidaceae alkaloids and investigation of mechanisms of action in treatment of Alzheimer's disease

Robust and predictive 3D-QSAR models for predicting the activities of novel oxadiazole derivatives as multifunctional anti-Alzheimer agents

Galantamine Based Novel Acetylcholinesterase Enzyme Inhibitors: A Molecular Modeling Design Approach

Design of vilazodone-donepezil chimeric derivatives as acetylcholinesterase inhibitors by QSAR, molecular docking and molecular dynamics simulations

A Comprehensive Analysis on Galantamine Based Hybrids for the Management of Alzheimer's Disease

Design, synthesis, and biological evaluation of novel xanthone-alkylbenzylamine hybrids as multifunctional agents for the treatment of Alzheimer’s disease

Molecular modeling of multi-target analogs of huperzine A and applications in Alzheimer's disease

Novel Thiadiazole Derivatives as Potential Anti‐Alzheimer Agent: Synthesis, Activity of Molecular Interactions and their in Silico Assessment

Computational analysis of novel drugs designed for use as acetylcholinesterase inhibitors and histamine H3 receptor antagonists for Alzheimer's disease by docking, scoring and de novo evolution

Evaluation Of Novel Dual Acetyl- And Butyrylcholinesterase Inhibitors As Potential Anti-Alzheimer'S Disease Agents Using Pharmacophore, 3d-Qsar And Molecular Docking Approaches